Foghorn Therapeutics and Eli Lilly are discontinuing their SMARCA2 degrader Fhd-909 after Phase I data fell short on efficacy.

/PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved an additional indication for...

JNJ trades at a 28% discount on valuation while LLY's cardiometabolic drugs drive 82% of revenue, each bet carries distinct growth and concentration risks.

JNJ trades at a 28% discount on valuation while LLY

Eli Lilly (NYSE: LLY) reported new Phase 2b and Phase 3 data for EloraTZP and retatrutide in obesity and type 2 diabetes. EloraTZP, which combines eloralintide with tirzepatide, produced significant weight loss and A1C reductions in adults with obesity and type 2 diabetes. Retatrutide, a triple agonist, also delivered strong weight and A1C outcomes in late-stage trials, indicating potential next-generation metabolic therapies. Management plans to move both candidates quickly toward...

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

Eli Lilly stock was at EUR 1,028.40 at 9:39 p.m. CEST on October 1, 2026, up 0.07 percent versus the

The Alliance for Christian Media and First Presbyterian Church of Marietta partner to bring compelling Christian preaching to broader audiences

Eli Lilly (NYSE:LLY) enters October on a combination obesity readout as healthcare leads the sector rotation.

Eli Lilly informó sobre análisis post hoc que mostraban que Foundayo estaba relacionado con una diabetes modelada más baja y un menor riesgo cardiovascular en adultos con obesidad.

Foghorn Therapeutics y Eli Lilly se asociaron en 2021 para desarrollar y comercializar productos oncológicos. Los despidos de la biotecnológica dejarán a la empresa con 65 empleados mientras se vuelve a centrar en sus programas de cartera patentados.

Second-quarter revenue rose 47.70 percent to USD 22.97 billion. Eli Lilly and Company stock costs EU

Eli Lilly (NYSE:LLY) enters today’s market discussion as sector themes, operations, and broader conditions draw attention.